Latest news with #ARVN
Business Insider
4 days ago
- Health
- Business Insider
Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance
Arvinas (ARVN) and Pfizer (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, MBC, whose disease progressed following prior treatment with cyclin-dependent kinase, CDK, 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation and have been simultaneously published in the New England Journal of Medicine. In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, among patients with an estrogen receptor 1, ESR1, mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant. The median PFS, as assessed by blinded independent central review, BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Investigator-assessed PFS was consistent with the BICR-assessed PFS. In patients with ESR1 mutations, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target of $16.00. The company's shares closed yesterday at $6.07. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Ahmad is an analyst with an average return of -5.3% and a 43.00% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. Currently, the analyst consensus on Arvinas Holding Company is a Moderate Buy with an average price target of $15.03, representing a 147.61% upside. In a report released on May 2, BTIG also maintained a Buy rating on the stock with a $16.00 price target. ARVN market cap is currently $475.9M and has a P/E ratio of -1.22. Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year. Most recently, in March 2025, Noah Berkowitz, the CMO of ARVN sold 8,658.00 shares for a total of $74,372.22.
